[HTML][HTML] ACC2022 丨Nonelidone FIDELITY Study ASCVD Subgroup Analysis Results Released! Write the" heart" chapter of chronic disease patient management

C Jiyan - laitimes.com
… death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) than
… event of cardiovascular death or hospitalization for heart failure in patients with a history of …

[引用][C] Dipeptidyl peptidase‐4 inhibitor approaches: 二肽基肽酶‐4 抑制剂类治疗药物

Z Bloomgarden - Journal of Diabetes, 2017 - Wiley Online Library
… , including CV death, non-fatal MI, and non-fatal stroke, over a … increase in risk of congestive
heart failure (CHF), significant … increased risk of hospitalization for heart failure, consistent in …

中風病人糖尿病之藥物治療及其心血管保護效果: GLP-1 RA 與SGLT2i 之更新回顧

謝鎮陽, 田凱仁 - 台灣中風醫誌, 2022 - airitilibrary.com
non-fatal stroke) or hospitalization for heart failure. In this review, we aimed to update the
cardiovascular evidences regarding GLP-1 RA and SGLT2i for physicians taking care of stroke …

Cardiovascular safety trials: Be careful what you wish for (心血管安全性研究: 当心你许的愿).

Z Bloomgarden, G Grunberger - Journal of Diabetes, 2014 - search.ebscohost.com
hospitalization, coronary revascularization, and heart failure … receiving placebo were
hospitalized for heart failure during the … death, non-fatal myocardial infarction, and non-fatal stroke. …

[引用][C] 依普利酮降低伴有心衰和左室收缩功能不全的急性心肌梗死患者随机分组后30d 死亡率

武俊平 - 世界核心医学期刊文摘: 心脏病学分册, 2005

[引用][C] 美托洛尔和卡维地洛对慢性心衰患者病因特异性死亡率和发病率的影响: COMET 研究

武敏 - 世界核心医学期刊文摘: 心脏病学分册, 2005

[引用][C] SGLT2 抑制剂应用于2 型糖尿病合并肾功能不全患者的心血管肾脏结局及安全性的系统评价和meta 分析

任明慧 - 2021 - 河北医科大学

[引用][C] 新发现的糖耐量异常: 心肌梗死后长期预后的重要预测指标

刘豫 - 世界核心医学期刊文摘: 心脏病学分册, 2005

[引用][C] 冠状动脉搭桥手术患者出院后结局的性别差异

郭俊 - 世界核心医学期刊文摘: 心脏病学分册, 2006

[引用][C] β 阻断剂对无心肌梗死或充血性心衰病史的冠状动脉疾病患者的死亡率和未来心肌梗死发生率的影响

刘健 - 世界核心医学期刊文摘: 心脏病学分册, 2005